Abstract
To determine the frequency of progressive MRI lesions shortly after radiotherapy for glioma with spontaneous improvement or stabilization, the authors studied a cohort of patients treated within two prospective phase III trials with radiotherapy only. In 9 out of 32 patients, the first post-radiotherapy MRI showed progressive enhancement. In 3 of these 9 the MRI improved or stabilized for 6 months without additional treatment. The authors conclude that patients with progressive lesions within 3 months after radiotherapy should not be eligible for phase II trials on recurrent glioma.
Publication types
-
Case Reports
-
Clinical Trial
-
Clinical Trial, Phase III
-
Multicenter Study
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Artifacts*
-
Astrocytoma / drug therapy
-
Astrocytoma / pathology
-
Astrocytoma / radiotherapy
-
Astrocytoma / surgery
-
Brain Edema / drug therapy
-
Brain Edema / etiology*
-
Brain Edema / pathology
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / pathology
-
Brain Neoplasms / radiotherapy*
-
Brain Neoplasms / surgery
-
Chemotherapy, Adjuvant
-
Clinical Trials, Phase III as Topic / standards
-
Cohort Studies
-
Combined Modality Therapy
-
Contrast Media
-
Cranial Irradiation*
-
Dacarbazine / administration & dosage
-
Dacarbazine / analogs & derivatives*
-
Dexamethasone / therapeutic use
-
Diagnosis, Differential
-
Disease Progression
-
Female
-
Follow-Up Studies
-
Gadolinium
-
Glioma / drug therapy
-
Glioma / pathology
-
Glioma / radiotherapy*
-
Humans
-
Lomustine / administration & dosage
-
Magnetic Resonance Imaging*
-
Male
-
Middle Aged
-
Patient Selection
-
Procarbazine / administration & dosage
-
Temozolomide
-
Vincristine / administration & dosage
Substances
-
Contrast Media
-
Procarbazine
-
Vincristine
-
Lomustine
-
Dacarbazine
-
Dexamethasone
-
Gadolinium
-
Temozolomide